Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma: Difference between revisions

From STARDIT
Jump to navigation Jump to search
VisualWikitext
wikispore>Pkdilena
No edit summary
wikispore>Pkdilena
No edit summary
Line 8: Line 8:
|location_parameter=Australia
|location_parameter=Australia
|location_link=No
|location_link=No
|URL_parameter=https://www.grants.gov.au/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b
|author_parameter={{author parameter
|author_parameter={{author parameter
|aut_nam=Portia Dilena
|aut_nam=Portia Dilena
Line 24: Line 25:
|inp_inp=1,225,487.40
|inp_inp=1,225,487.40
|inp_currency=AUD
|inp_currency=AUD
|inp_url=https://www.grants.gov.au/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b
}}
}}
}}
}}

Revision as of 04:16, 6 April 2023

Description: Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
Dates

State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-04-06

Report authors
Portia Dilena (link)
Aims
maximise survival of these young Australians
Category
research

Inputs

individual

Eliza Hawkes


Task: Lead Chief Investigator
Compensation: paid
funding

(link)


1,225,487.40 (AUD)

Outputs and impacts

Retrieved from "https://stardit.wikimedia.org.au/w/index.php?title=Employing_rational_novel_agent_combination_therapy_to_improve_transplant_cure_rates_for_relapsed/refractory_Hodgkin_Lymphoma&oldid=325"